In today’s recent session, 0.58 million shares of the Cellectar Biosciences Inc (NASDAQ:CLRB) have been traded, and its beta is 0.95. Most recently the company’s share price was $1.71, and it changed around -$0.06 or -3.67% from the last close, which brings the market valuation of the company to $69.16M. CLRB at last check was trading at a discount to its 52-week high of $4.45, offering almost -160.23% off that amount. The share price’s 52-week low was $1.66, which indicates that the recent value has risen by an impressive 2.92% since then. We note from Cellectar Biosciences Inc’s average daily trading volume that its 10-day average is 0.48 million shares, with the 3-month average coming to 269.39K.
Cellectar Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CLRB as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Cellectar Biosciences Inc is expected to report earnings per share of -0.3 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
Instantly CLRB has been showing red trend so far today with a performance of -3.67% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.1800 on recent trading dayincreased the stock’s daily price by 21.56%. The company’s shares are currently down -38.45% year-to-date, but still down -20.33% over the last five days. On the other hand, Cellectar Biosciences Inc (NASDAQ:CLRB) is -19.19% down in the 30-day period. We can see from the shorts that 1.84 million shares have been sold at a short interest cover period of 8.34 day(s).
The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 85.75% from its current value. Analyst projections state that CLRB is forecast to be at a low of $12 and a high of $12.
Cellectar Biosciences Inc (CLRB) estimates and forecasts
Cellectar Biosciences Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -47.54 percent over the past six months and at a 39.37% annual growth rate that is well above the industry average of 10.40%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 25.00% in revenue this quarter, and will report an increase of 55.41% in the next quarter.
Forecasts for the next quarter put sales growth at �.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 41.77%.
CLRB Dividends
Cellectar Biosciences Inc’s next quarterly earnings report is expected to be released on 2024-Nov-18.
Cellectar Biosciences Inc (NASDAQ:CLRB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.84% of Cellectar Biosciences Inc shares, and 34.55% of them are in the hands of institutional investors. The stock currently has a share float of 35.56%.
